Technology search

show all patents

Technology search by keyword

Results 1 - 10 of 10

Brenner, Schrotz-King, Bhardwaj

Colorectal Cancer Diagnostic (P-1455)

Keywords: Diagnostics

Sigmoidoscopy and colonoscopy, the current gold standards for detection of CRC are limited by several disadvantages, such as high costs, limited resources and poor compliance. Therefore, other cost-effective and sensitive methods are urgently needed for the early detection of colorectal cancer. The need of an efficient and cheap test is very important from the health economic standpoint. Using blood samples this invention offers a set of proteins that can be used as a diagnostic tool for accurate diagnosis, and/or monitoring of therapy in colorectal cancer (CRC). The panel has the sensitivity of 83% for detecting early stage CRC at specificity 80% and the AUC of 0.86. For detecting all-stage CRC an AUC of s 0.82 is observed. more...

Waterboer, Hufnagel, Lueong Smiths, Pawlita, Hoheisel, Willhauck-Fleckenstein

Peptide array for Chlamydia trachomatis diagnosis (P-1391)

Keywords: Diagnostics, Research Tools

We have developped a peptide array comprising at least 100 polypeptides expressed or expressible from a Chlamydia trachomatis genome or epitopes fragment thereof. The technology can be used for diagnosing cervical carcinoma or for diagnosing a Chlamydia spp. infection in a patient.

Burwinkel, Brenner, Gündert, Edelmann

Prognostic methylation-based classifier for colorectal cancer (ProMCol) (P-1348)

Keywords: Diagnostics

Colorectal cancer (CRC) is the third most common cancer worldwide accounting for 1.36 million new cases annually. Harmful overtreatment of patients with colorectal cancer (CRC) due to imprecise prognosis prediction based on the traditional tumor, node, metastasis system highlights the need of additional prognostic markers. Our classifier (ProMCol) allows predicting disease specific survival of colorectal cancer patients. This can guide treatment decisions and therefore avoid unnecessary side effects associated with chemotherapy, if the survivability prediction is positive. more...

Brenner, Zhang

Mortality prediction through DNA methylation biomarkers (P-1333)

Keywords: Diagnostics

Getting to know you chances of dying can be daunting but also can be rather useful and fascinating. The kit predicts all-cause mortality independent of underlying diseases or the ?epigenetic clock?. It has been validated through a 14 year long patient study.

Brenner, Chen

Biomarker panel for diagnosing colorectal cancer (P-1214)

Keywords: Diagnostics

The invention offers a plasma protein biomarker set that can be used as a diagnostic tool for diagnosis and stratification of colorectal cancer.

Burwinkel, Yang, Peng, Cike, Schneeweiss

Plasma S100P and hyaluronic acid level as prognostic and treatment monitoring markers for metastatic breast cancer (P-1157)

Keywords: Diagnostics, Research Tools

The present invention comprises the use of two serum/plasma markers for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers outperform established ones like the number of circulating tumor cells (CTCs).

Herzig, Berriel Diaz, de Guia

MicroRNAs Modulating the Effect of Glucocorticoid Signaling (P-1137)

Keywords: Diagnostics

The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.

Lichter, Pfister, Witt, Jones, Sturm, Plass, Korshunov, Pfaff, Jabado

Histone mutations as marker for Glioblastoma (P-1012)

Keywords: Diagnostics

This technology was achieved by a cooperation between McGill University and DKFZ. Brain tumours, such as the highly aggressive glioblastoma multiforme (GBM), are currently the leading cause of cancer-related mortality and morbidity in children. Current diagnosis of brain cancers involve MRI, PET and CT scans, angiographies, followed by biopsies performed either during the resection of the tumor or as a separate procedure via a burr hole. A blood-based test would provide a more economical, i.e accessible and less invasive diagnostic tool. The GBM specific biomarker has been patented and is available for licensing i.e. for companion diagnostics. more...

von Deimling, Buckel, Balss, Pusch

Diagnosis of glioblastoma and acute myeloid leukaemia by (D)-2-hydroxyglutarate test (P-977)

Keywords: Diagnostics

Diagnosis and monitoring of IDH1/IDH2/IDH3 dependent diseases such as: Glioblastomas, astrocytoma, oligodendrogliomas, oligoastrocytoma, acute myeloid leukaemia (AML), chondrosarcoma, intrahepatic cholangiocarcinoma, angioimmunoblastic T cell lymphoma. The technolgy describes a patented test, which is a simple and robust enzymatic assay with a readout in 3 hours. The test is suitable for 96-/384-well format, less expensive/time-consuming and high-throughput possible in opposite to established GC-MS test. more...

Moldenhauer, Scheffzek, Parret

Monoclonal Antibody against Neurofibromin: Diagnostic and Prognostic Marker for Glioma Treatment (N terminal antibody: mAb NF1-5.16) (P-897)

Keywords: Diagnostics

Monoclonal Antibody against Neurofibromin as a diagnostic and prognostic Marker for Glioma Treatment. The proof of concept is established with Biopsy Material. The antibody is fast, reliable & ready to use.

to top
powered by webEdition CMS